Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Boehringer Ingelheim Pharma Kg

Boehringer Ingelheim International Gmbh

Helmut Wittneben

Frank Himmelsbach

Georg Dahmann

Alexander Pautsch

Martin Steegmaier

Steffen Steurer

Walter Spevak

Andreas Schoop

Martin Lenter

Bernd Krist

Anthony S Prokopowicz

Gisela Schnapp

Armin Heckel

Wolfgang Grell

Rainer Walter

Norbert Redemann

Jacobus C Van Meel

Anthony S Prokopowicz, Iii

Robert Haigh

Gisela Schapp

The present invention relates to trisubstituted pyrimidines of formula (I) wherein

Pyrimidine derivatives

The present invention relates to trisubstituted pyrimidines of formula (I) wherein0Rto Rare defined as in claim, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

The present invention relates to trisubstituted pyrimidines of formula (I) wherein0Rto Rare defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

The present invention relates to indolinones of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

Indolinones having kinase-inhibiting activity

Growing community of inventors

Schriesheim, Germany

Helmut Wittneben